bioMerieux SA Forecast, price target & analysts
bioMerieux SA Target price 2025 - Analyst rating & recommendation
bioMerieux SA Classifications & Recommendation:
bioMerieux SA Price Target
| Target Price | €125.36 |
| Price | €118.60 |
| Potential |
5.70%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target bioMerieux SA 2026 .
The average bioMerieux SA target price is €125.36.
This is
5.70%
register free of charge
€135.00
13.83%
register free of charge
€90.00
24.11%
register free of charge
|
|
| A rating was issued by 16 analysts: 11 Analysts recommend bioMerieux SA to buy, 3 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the bioMerieux SA stock has an average upside potential 2026 of
5.70%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 3.98 | 4.26 |
| 8.31% | 7.07% | |
| EBITDA Margin | 22.45% | 23.91% |
| 3.73% | 6.53% | |
| Net Margin | 10.87% | 12.06% |
| 11.83% | 10.91% |
13 Analysts have issued a sales forecast bioMerieux SA 2025 . The average bioMerieux SA sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an bioMerieux SA EBITDA forecast 2025. The average bioMerieux SA EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 bioMerieux SA Analysts have issued a net profit forecast 2025. The average bioMerieux SA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 3.67 | 4.36 |
| 21.12% | 18.80% | |
| P/E | 27.21 | |
| EV/Sales | 3.29 |
12 Analysts have issued a bioMerieux SA forecast for earnings per share. The average bioMerieux SA EPS is
This results in the following potential growth metrics and future valuations:
Current bioMerieux SA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| MIDCAP PARTNERS |
Locked
➜
Locked
|
Locked | Mar 09 2025 |
| ESN/CIC MARKET SOLUTIONS |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| MIDCAP PARTNERS |
Locked
➜
Locked
|
Locked | Dec 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HSBC:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
MIDCAP PARTNERS:
Locked
➜
Locked
|
Mar 09 2025 |
|
Locked
ESN/CIC MARKET SOLUTIONS:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
MIDCAP PARTNERS:
Locked
➜
Locked
|
Dec 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
